A new injectable formulation of Keytruda, a leading cancer treatment, is set to significantly reduce the time patients spend in NHS facilities across the UK. This advancement in immunotherapy not only promises to streamline cancer care but also aims to enhance the overall experience for patients undergoing treatment.
Transforming Cancer Treatment
The injectable version of Keytruda, which is scientifically known as pembrolizumab, is designed to bolster the body’s immune response against cancer cells. Previously, patients received the drug via intravenous infusion, a process that could take over an hour. With the new injection, this time is expected to be slashed to just a few minutes, providing substantial relief to both patients and healthcare providers.
Shirley Xerxes, an 86-year-old from St Albans, was among the first individuals to receive the new treatment at the Mount Vernon Cancer Centre. Reflecting on her experience, she stated, “I was in the chair for a matter of minutes instead of an hour or more. It’s made such a difference and gives me more time to live my life, including spending more time gardening.”
This innovation is anticipated to benefit approximately 14,000 patients annually in England who commence treatment with Keytruda, which is recognised for its efficacy in managing 14 different cancer types, including lung, head and neck, cervical, and breast cancers.
Streamlined Administration
The new Keytruda formulation will allow for administration every three weeks as a one-minute injection or every six weeks as a two-minute injection, tailored to the specific type of cancer being treated. This method represents a significant shift in the approach to cancer therapies within the NHS, as it is the third immunotherapy drug to be offered in an injectable format, following the introduction of Opdivo (nivolumab) in select hospitals last year.
Professor Peter Johnson, NHS England’s national clinical director for cancer, spoke on the impact of this transition. “Managing cancer treatment and regular hospital trips can be really exhausting. If we can do this in a much shorter period of time, it frees up space in our chemotherapy units and means we can start thinking about giving treatment in the community and away from hospitals,” he explained.
Understanding Immunotherapy
Immunotherapy, including Keytruda, operates by enabling the immune system to identify and combat cancer cells that often evade detection. Cancer cells can produce proteins that signal the immune system to refrain from attacking, effectively cloaking themselves. The mechanism of immunotherapy helps to unmask these cells, allowing the body’s natural defenses to engage and eliminate the malignancy. This groundbreaking discovery earned scientists James Allison and Tasuku Honjo the Nobel Prize for Medicine in 2018.
First approved for treating skin cancer, Keytruda has since expanded its applications, becoming the best-selling prescription drug globally, with projected sales reaching $30 billion (£22 billion) in 2025.
Economic Implications and Future Prospects
While NHS England has not disclosed the financial specifics of the deal with Merck Sharp & Dohme (MSD), it is believed that the cost for the injectable version will be comparable to the intravenous formulation. Keytruda has generated approximately $180 billion in sales since its inception over a decade ago, marking it as one of the most lucrative medicines in history. As its patent protections are set to expire in the coming years, there is anticipation of the emergence of generic versions, which may further increase accessibility for patients.
In response to criticisms regarding the timing of the new formulation’s release, MSD has asserted that the injectable version provides significant advantages for hospitals, including reduced administration times and decreased strain on NHS resources.
Why it Matters
The introduction of the injectable Keytruda not only represents a significant advancement in cancer treatment but also embodies a transformative shift in patient care within the NHS. By minimising the time spent in hospital settings, this innovation allows patients to reclaim precious moments in their daily lives while also easing the burden on healthcare facilities. As the healthcare landscape continues to evolve, such breakthroughs are crucial in enhancing the efficiency of treatment and improving the overall quality of life for individuals battling cancer.
